The invention provides a novel polymorph of clopidogrel hydrogen sulfate and processes for its preparation.

The present invention relates to novet crystalline forms of abacavir sulfate, to processes for their preparation and to pharmaceutical compositions containing them.

Process for Purification of Darbepoetin Alfa The present invention provides sequential chromatography steps and conditions for purification of a recombinant protein, especially recombinant darbepoetin alfa.

The present invention relates to a process for preparing substituted sulfoxides either as a single enantiomer or in an enantiomerically enriched form Thus, racemic omeprazole is reacted with (S)-camphorsulfonyl chloride to form a diastereomeric mixture and the diastereomers are separated by fractipnal crystallizatio...

The present invention relates to novel hydrate of irbesartan, amorphous irbesartan hydrate and pharmaceutical compositions containing them. The present invention also relates to novel processes for preparing crystalline form-A, crystalline form-B and amorphous form of irbesartan. Thus, for example, irbesartan and wa...

The present invention relates to a process for separation of desired diastereomeric pair from a mixture of diastereomeric pairs thereby obtaining nebivolol intermediates. Thus, the mixture of (+)-[1S*(R*)]-6-fluorO"3,4-dihydro-α-[[phenylmethyl)amino]methyI]-2H-1"benzopyran-2-methanol, (±)-[1S*(S*)]-6-duoro-3,4-dinyd...

The present invention relates to crystalline alfuzosin base and processes for preparation of the said crystalline solid. Thus, for example, alfuzosin base (HPLC purity: 97%) is added to methanol and heated to reflux to form a clear solution, the solution is cooled to 25 - 30°C and stirred for 12 hours at the same te...

The present invention provides solid form of faropenem free acid, its hydrates and processes for their preparation thereof. Thus, for example, dissolving an alkali metal salt of faropenem in water, adjusting the pH of the solution formed with an acid to below about 2.5 and collecting the precipitated solid to obtain...

The present invention discloses novel and stable polymorphs of rimonabant, its hydrates and solvates, to the processes for their preparation and to pharmaceutical compositions comprising them. The present invention further discloses novel and stable amorphous form of rimonabant, process for its preparation and a pha...

The present invention provides an improved and commercially viable process for preparation of erlotinib substantially free of N-methoxyethyl impurity, namely N-[(3-ethynylphenyl)-(2-methoxyethyl)]-6,7-bis(2-methoxyethoxy)-4- quinazolinamine, and its pharmaceutically acceptable acid addition salts thereof in high ...

The present invention relates to a process for obtaining pure aprepitant substantially free of undesired diastereomeric isomer, namely 5-[2(S)-[1(RS)-[3,5-bis(trifluoromethyl)"phenyl)ethoxy]-3-(S)-(4-fluorophenyl)-morpholin-4-yl-methyl]-3,4-dihydro-2H-1,2,4-triazol-3-one. The present invention further provides an im...

The present invention relates to a process for preparing a key intermediate of cefprozil and use of this intermediate in the preparation of cefprozil thereby avoiding impurity-causing self-acylation. [R"(Z)]-[4-hydroxy-a-[(3-methoxy-1-methyl-3-oxo-1-propenyl)amino]] benzeneacetic acid, mono potassium salt is reacte...

The present invention provides novel crystalline forms of aripiprazole and processes for their preparation.

The present invention provides an enantioselective process for preparing substituted benzimidazoles either as a single enantionr)er or In an enantiomerically enriched form.

The present invention relates to eprosartan mesylate particles having relatively larger surface area, to the methods for the manufacture of said crystalline particles, and to pharmaceutical compositions comprising said crystalline particles. The present invention further relates to crystalline solid of eprosartan ac...

The present invention provides an improved and commercially viable process for the preparation of rimonabant substantially free of amide impurity, namely 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl-4-methyl-pyrazole-3-carboxamide and its pharmaceutically acceptable acid addition salts thereof. Thus, for example, 5-(4-c...

The present invention provides an improved and commercially viable process for preparation of substantially enaritiomerically pure esomeprazole in neutral form or as a pharmaceutically acceptable salt or as its solvates including hydrates. Thus, for example, a compound containing a mixture of 1-(S)- camphorsulfo...

The present invention provides an improved and commercially viable process for preparation of eprosartan and its pharmaceutically acceptable acid addition salts thereof in high purity and in high yield. Thus, for example, methyl 4-[[2-butyl-5-formyl-1H-imidazol-1-yl] methyl] ben2oate is reacted with ethyl 2-carboxy-...

The present invention relates to two novel and stable crystalline forms of atovaquone, to the processes for their preparation and to pharmaceutical compositions comprising them. The present invention also provides crystalline particles of atovaquone having a specific surface area of from about 0.7 m /g to about 4 m ...

The present invention provides a novel and stable hydrated form of eriotinib free base, and a process for its preparation thereof. The present invention also provides a process for preparation of eriotinib hydrochloride crystalline polymorph A substantially free of polymorph B. The present invention further relates ...

The invention provides a process for preparing intermediate of ezetimibe, which shows hypocholesterolemic activity. Thus 3-[5-(4-fluorophenyl)-1,5-dioxopentyl]-4-phenyl-2-Oxazolidinone is reduced with (-)-DIP chloride to obtain 3-[(5S)-5-(4-fluorophenyl)-5-hydroxy-1-oxopentyl]-4-phenyl-2-Oxazolidinone. ...

The present invention relates to a high assayed esomeprazole magnesium dihydrate substantially free of its trihydrate form. The present invention further provides an improved and commercially viable process for preparation of high assayed esomeprazole magnesium dihydrate substantially free of its trihydrate form. Th...

The present invention provides an improved and efficient process for preparation of highly pure amorphous rabeprazole sodium. Thus, for example, rabeprazole is dissolved in an alcoholic sodium hydroxide solution followed by carbon treatment, the resulting filtrate is distilled under vacuum at 50 - 52°C followed by c...

A novel crystalline form of 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1- piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (risperidone) and a pharmaceutical composition comprising it.

Valsartan of formula I:is prepared by hydrolysis of valsartan benzyl ester with an alkali metal hydroxide, washing with an organic solvent, acidifying with hydrochloric acid and isolating valsartan from the reaction mixture.

The present invention relates to a process for the preparation of dorzolamide hydrochloride crystalline polymorph. Thus, for example, dissolving dorzolamide free base in dimethylsulfoxide, adding hydrochloric acid, maintaining at 0°C -20°C, adding an alcohol and collecting the solid from the contents by filt...

The present invention relates to novel amorphous and crystalline forms of efavirenz, processes for their preparation and pharmaceutical compositions containing them. In accordance with the present invention efavirenz crude is dissolved in acetone at 25°C - 30°C, the solution is slowly added to water for 30 m...